Breast Cancer Res. 2009;11(6):111. Epub 2009 Nov 26.

PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2?

Abstract

Poly(ADP-ribose) polymerase (PARP) inhibitors have been explored as therapeutic agents for the treatment of hereditary breast and ovarian cancers harboring mutations in BRCA1 or BRCA2. In a new study, Inbar-Rozensal and colleagues show that phenanthridine-derived PARP inhibitors promote cell cycle arrest and cell death in breast cancer cells lacking BRCA1 and BRCA2 mutations and prevent the growth of tumors from xenografts of these cells in immunocompromised mice. These results suggest a potential broader utility of PARP-1 inhibitors in the treatment of breast cancer, although further mechanistic studies are needed.

Comment on

Breast Cancer Res. 2009;11(6):R78.

PMID:: 20017885; [PubMed - indexed for MEDLINE]
PMCID: PMC2815546

Free PMC Article

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Breast Cancer - MedlinePlus Health Information

Libraries

LinkOut Holdings

Supplemental Content

Related citations

The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors. [Int J Biol Sci. 2006]
The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors.
De Soto JA, Wang X, Tominaga Y, Wang RH, Cao L, Qiao W, Li C, Xu X, Skoumbourdis AP, Prindiville SA, et al. Int J Biol Sci. 2006; 2(4):179-85. Epub 2006 Jun 10.
A selective eradication of human nonhereditary breast cancer cells by phenanthridine-derived polyADP-ribose polymerase inhibitors. [Breast Cancer Res. 2009]
A selective eradication of human nonhereditary breast cancer cells by phenanthridine-derived polyADP-ribose polymerase inhibitors.
Inbar-Rozensal D, Castiel A, Visochek L, Castel D, Dantzer F, Izraeli S, Cohen-Armon M. Breast Cancer Res. 2009; 11(6):R78. Epub 2009 Nov 9.
The potential of PARP inhibitors in genetic breast and ovarian cancers. [Ann N Y Acad Sci. 2008]
The potential of PARP inhibitors in genetic breast and ovarian cancers.
Drew Y, Calvert H. Ann N Y Acad Sci. 2008 Sep; 1138:136-45.
Review The clinical development of inhibitors of poly(ADP-ribose) polymerase. [Ann Oncol. 2011]
Review The clinical development of inhibitors of poly(ADP-ribose) polymerase.
Calvert H, Azzariti A. Ann Oncol. 2011 Jan; 22 Suppl 1:i53-9.
Review BRCA in breast cancer: from risk assessment to therapeutic prediction. [Drug News Perspect. 2009]
Review BRCA in breast cancer: from risk assessment to therapeutic prediction.
Diamond JR, Borges VF, Eckhardt SG, Jimeno A. Drug News Perspect. 2009 Dec; 22(10):603-8.

See reviews... See all...

Cited by 1 PubMed Central article

Cordycepin blocks lung injury-associated inflammation and promotes BRCA1-deficient breast cancer cell killing by effectively inhibiting PARP. [Mol Med. 2011]
Cordycepin blocks lung injury-associated inflammation and promotes BRCA1-deficient breast cancer cell killing by effectively inhibiting PARP.
Kim H, Naura AS, Errami Y, Ju J, Boulares AH. Mol Med. 2011 Sep-Oct; 17(9-10):893-900. Epub 2011 May 13.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
References for this PMC Article
Citation referenced in PubMed article. Only valid for PubMed citations that are also in PMC.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Free in PMC
Free full text articles in PMC
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2?
PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2?
Breast Cancer Res. 2009 ;11(6):111. Epub 2009 Nov 26 .

PubMed
Biomarkers for epithelial-mesenchymal transitions.
Biomarkers for epithelial-mesenchymal transitions.
J Clin Invest. 2009 Jun ;119(6):1429-37. doi: 10.1172/JCI36183. Epub 2009 Jun 1 .

PubMed
Lactococcus lactis, an alternative system for functional expression of periphera...
Lactococcus lactis, an alternative system for functional expression of peripheral and intrinsic Arabidopsis membrane proteins.
PLoS One. 2010 Jan 20 ;5(1):e8746.

PubMed
Neuronatin: a new inflammation gene expressed on the aortic endothelium of diabe...
Neuronatin: a new inflammation gene expressed on the aortic endothelium of diabetic mice.
Diabetes. 2008 Oct ;57(10):2774-83. Epub 2008 Jun 30 .

PubMed
Diagnosis of hepatocellular carcinoma.
Diagnosis of hepatocellular carcinoma.
World J Gastroenterol. 2009 Mar 21 ;15(11):1301-14.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to: